{
    "nct_id": "NCT05747625",
    "official_title": "Study Evaluating 89Zr Panitumumab for Assessment of Indeterminate Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma",
    "inclusion_criteria": "* Age >= 19 years\n* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck\n* Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed\n* Must have evidence of indeterminate metastatic squamous cell carcinoma (SCC) based on 18F-fluorodeoxyglucose (FDG)-PET/CT or Primary SCC with suspicious Lymph Nodes on CT prior to surgical removal\n* Hemoglobin >= 9gm/dL\n* White blood cell count > 3000/mm^3\n* Platelet count >= 100,000/mm^3\n* Serum creatinine =< 1.5 times upper reference range\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment\n* History of infusion reactions to other monoclonal antibody therapies\n* Pregnant (based on screening serum pregnancy test and day 0 urine pregnancy test administered before unlabeled panitumumab), or breastfeeding\n* Magnesium or potassium lower than the normal institutional values\n* Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis\n* Severe renal disease or anuria\n* Known hypersensitivity to deferoxamine or any of its components",
    "miscellaneous_criteria": ""
}